Please login to the form below
Combination treatment
This page shows the latest Combination treatment news and features for those working in and with pharma, biotech and healthcare.
Takeda announces CHMP recommendation for Adcetris in Hodgkin lymphoma
combination treatment in adults with previously untreated CD30+ stage 3 Hodgkin lymphoma. ... The study met its key primary and secondary endpoints, demonstrating a statistically significant improvement in modified progression-free survival and overall
Latest news
-
EC approves Otsuka and Astex’s Inaqovi for acute myeloid leukaemia
Current treatment options for adults with AML range from hospital-administered intravenous (IV) chemotherapy infusions or, for those who are unable to receive chemotherapy, regimens based on parenterally administered hypomethylating agents.
-
IO Biotech announces new data supporting its therapeutic cancer vaccine
Qasim Ahmad, chief medical officer at IO Biotech, said: "We believe our cancer vaccine in combination with an anti-PD-1 antibody could change the treatment paradigm for multiple tumour types ... In August, Merck &Co – known as MSD outside the US and
-
Merck receives EC approval for Keytruda combination in gastric cancer
a combination treatment for certain gastric cancer patients. ... The therapy is now approved in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or
-
Merck’s Keytruda combination shows promise in late-stage breast cancer study
Merck &Co – known as MSD outside the US and Canada – has shared positive results from a late-stage study of its Keytruda (pembrolizumab) combination in certain breast cancer patients. ... The phase 3 KEYNOTE-756 trial has been evaluating the
-
Merck granted positive CHMP opinion for Keytruda combination in gastric cancer
Merck &Co’s – known as MSD outside the US and Canada – Keytruda (pembrolizumab) has been recommended by the European Medicines Agency’s human medicines committee as part of a combination treatment ... The Committee for Medicinal Products for
More from news
Approximately 0 fully matching, plus 369 partially matching documents found.
Latest Intelligence
-
Tuberculosis – why it remains a major global public health challenge
TB combination treatment regimens into phase 2 clinical development. ... The MRI will conduct non-clinical and clinical studies of these candidates to determine their potential for inclusion in new affordable combination treatment regimens for TB with
-
As COVID-19 takes over the world, biopharma fights back
A combination HIV treatment: AbbVie’s Kaletra. In an unprecedented move, AbbVie has suspended its patents on its combination HIV drug Kaletra, after it was identified as having potential against ... The combination drug was first included in Chinese
-
Deal Watch April 2016
Another deal worth pondering about is the $265m exclusive license by AstraZeneca (AZ) of the approved Zurampic (lesuranid) plus a fixed dose combination with allopurinol for treatment of gout. ... 85 . Dong A (SK). Tobira (US). Cross license. Evogliptin
-
Pharma deals in April 2015
No deal terms were disclosed. The initial development plan will look at the combination therapy as a potential treatment for NHL. ... The treatment combines an antibody engineered to target CD19 with the cancer-killing agent maytansinoid.
-
Pharma deals during July 2014
The acquisition of Almirall's respiratory business enhances AZ's respiratory franchise bringing a portfolio of marketed and developmental single and combination products for the treatment of asthma and COPD. ... tremelimumab. Existing partners
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
Latest from PMHub
-
What does the future hold for Light-chain Amyloidosis?
approval in combination with CyBorD for the treatment of newly diagnosed adult patients with AL amyloidosis. ... Prior to the approval of a new combination treatment for use across Europe, we conducted the first wave of our research to generate a
-
Oncosec
body. OncoSec has built a deep and diverse clinical pipeline utilizing TAVO as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; ... Results from recently completed
-
Marketing strategy in complex environments
The last few years have seen influential scientific advances, resulting in subtle shifts in how pharma tackles disease treatment. ... The treatment of aggressive diseases often benefits very noticeably from combination therapy, especially when involving
More from PMHub
Approximately 1 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- COVID-19 could be key in identifying viruses with pandemic potential
- Novo Nordisk Foundation commits €127m for new cell therapy facility
- Alzheimer’s Research UK launches ‘Change The Ending’ campaign
- AstraZeneca and Daiichi Sankyo share positive results from phase 3 breast cancer study
- ICR and Merck renew strategic alliance for development of new cancer drugs
- DeepMind’s AI tool classifies effects of mutations in genetic diseases
No results were found
PMHub
nzyme
The nzyme group focuses on the three fundamentals that enable full patient access - Education, Access & Activation. Our specialist...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
